Advertisement

American Journal of Cardiovascular Drugs

, Volume 10, Issue 6, pp 413–418 | Cite as

Vorapaxar

Adis R&D Profile

Abstract

Merck & Co. is developing vorapaxar (SCH 530348), a thrombin receptor antagonist, for the prevention and treatment of arterial thrombosis. Vorapaxar is currently being evaluated in two large-scale multinational phase III trials (TRA*CER and TRA 2°P-TIMI 50) for the treatment and prevention of cardiac events in almost 30 000 patients with acute coronary syndromes and those with prior myocardial infarction or stroke, as well as patients with acute coronary syndrome and those with peripheral arterial disease. This review discusses the development history and scientific profile of this new compound.

1. Introduction

Merck & Co. is developing vorapaxar (SCH 530348), a thrombin receptor antagonist, for the prevention and treatment of arterial thrombosis. It is known that thrombin stimulates specific cell receptors, called protease-activated receptors (PAR), involved in proliferative and pro-inflammatory processes. This effect of thrombin may have implications in thrombosis,...

References

  1. 1.
    Merck. New Merck Begins Operations. www.merck.com, 05 Nov 2009.Google Scholar
  2. 2.
    Schering-Plough Corporation. Schering-Plough Announces Initiation of Two Phase III Clinical Trials for Novel Selective Antiplatelet Therapy (TRA-SCH 530348). www.schering-plough.com, 18 Apr 2007.Google Scholar
  3. 3.
    Merck and Co. Merck Announces Completion of Patient Enrollment in Phase III TRA-2°P-TIMI 50 Trial of SCH 530348, a Novel, Oral Antiplatelet PAR-1 Inhibitor. www.merck.com, 14 Nov 2009.Google Scholar
  4. 4.
    Merck and Co. Inc. Merck Announces Second-Quarter 2010 Financial Results. www.merck.com, 30 Jul 2010.Google Scholar
  5. 5.
    Schering-Plough Corporation. Schering-Plough’s Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study. www.schering-plough.com, 12 Mar 2009.Google Scholar
  6. 6.
    Schering-Plough Corporation. Schering-Plough’s Novel Oral Thrombin Receptor Antagonist Meets Primary Endpoint in Phase II Trial. www.schering-plough.com, 24 Mar 2007.Google Scholar
  7. 7.
    Schering-Plough Corporation. Schering-Plough Reports Two Phase II Studies of Thrombin Receptor Antagonist (TRA) Build on Findings from Previous Phase II Study — Part B. www.schering-plough.com, 22 Nov 2007.Google Scholar
  8. 8.
    Schering-Plough Corporation. Schering-Plough Reports Two Phase II Studies of Thrombin Receptor Antagonist (TRA) Build on Findings from Previous Phase II Study — Part A. www.schering-plough.com, 22 Oct 2007.Google Scholar
  9. 9.
    Scherin Plough Corporation. Schering-Plough Reports Two Phase II Studies of Thrombin Receptor Antagonist (TRA) Build on Findings from Previous Phase II Study — Part C. www.schering-plough.com, 22 Nov 2007.Google Scholar
  10. 10.
    Schering-Plough Corporation. FDA Grants Fast Track Designation to Schering-Plough for its Thrombin Receptor Antagonist SCH 530348. www.schering-plough.com, 20 Apr 2006.Google Scholar
  11. 11.
    Schering-Plough Corporation. Schering-Plough Reports Financial Results for First Quarter of 2006. www.schering-plough.com, 20 Apr 2006.Google Scholar
  12. 12.
    Schering-Plough Corporation. Schering-Plough Highlights R&D Pipeline and Product Portfolio at Analysts and Portfolio Managers Meeting. www.schering-plough.com, 01 Nov 2005.Google Scholar
  13. 13.
    Reyderman L, Kosoglou T, Tseng J, et al. The effect of food and antacid on pharmacokinetics of SCH 530348 in healthy subjects. 110th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. S21 abstr. PI-42, 18 Mar 2009. Available from URL: http://www.nature.com.Google Scholar
  14. 14.
    Kosoglou T, Reyderman L, Fales RR, et al. Pharmacodynamics and pharmacokinetics of a novel protease-activated receptor antagonist SCH 530348. Circulation 2005 Oct 25; 112 (Suppl.): 32, No. 17.Google Scholar
  15. 15.
    Kosoglou T, Reyderman L, Kasserra C, et al. Optimizing dose of the novel thrombin receptor antagonist SCH 530348 based on pharmacodynamics and pharmacokinetics in healthy subjects. Clinical Pharmacology and Therapeutics 2008 Mar; 83 (Suppl. 1): 55.Google Scholar
  16. 16.
    Goto S, Yamaguchi T, Ikeda Y, et al. Phase II trial of the novel antipaltelet agent, SCH 530348, in Japanese patients with non-ST segment elevation acute coronary syndromes. ESC Congress 2008: Annual Congress of the European Society of Cardiology. abstr. P4767, 30 Aug 2008. Available from URL: http://www.escardio.org.Google Scholar
  17. 17.
    Moliterno DJ, Becker RC, Jennings LK, et al. Results of a multinational randomized, double-blind, placebo-controlled study of a novel thrombin receptor antagonist (SCH 530348) in percutaneous coronary intervention. 56th Annual Scientific Session of the American College of Cardiology: Late Breakers i2 Summit. (plus oral presentation), 24 Mar 2007.Google Scholar
  18. 18.
    Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009 14 Mar; 373: 919–28, No. 9667.PubMedCrossRefGoogle Scholar
  19. 19.
    Kosoglou T, Tiessen R, Van Vliet AA, et al. Safety and tolerability of SCH 530348, a novel antiplatelet agent, after single and multiple oral dosing in healthy subjects. ESC Congress 2008: Annual Congress of the European Society of Cardiology. abstr. P1340, 30 Aug 2008. Available from URL: http://www. escardio.org. Summary in 2 parts (Part A).Google Scholar
  20. 20.
    Reyderman L, Kosoglou T, Kasserra C, et al. Lack of ethnic differences in the pharmacodynamics and pharmacokinetics of SCH 530348 a novel oral antiplatelet agent in Japanese and caucasion subjects. 110 th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. S21 abstr. PI-41, 18 Mar 2009. Available from URL: http://www.nature.com.Google Scholar
  21. 21.
    Chintala M, Ahn H-S, Foster C, et al. Pharmacologica profile of SCH 53048, a novel oral antiplatelet agent selective for the protease-activated receptor-1.81st Annual Scientific Sessions of the American Heart Association. 374 abstr. 1710, 8 Nov 2008. Available from URL: http://scientificsessions. americanheart.org.Google Scholar

Copyright information

© Adis Data Information BV 2010

Personalised recommendations